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Summary: Fifty-one patients with mild hypertension were evaluated in relation to the plasma concentrations
of coagulation and fibrinolysis factors äs well äs for the aggregability of their platelets.
In a considerable number of the patients (18/51), a significantly enhanced in vitro ADP
aggregation was found. In the coagulation line significant increases could be demonstrated in fibrinogen,
fibrin monomers and thrombin-antithrombin III. The fibrinolysis System showed significant increases for D-
dimers, tissue plasminogen activator antigen and plasminogen activator Inhibitor, whereas the tissue plasmin-
ogen activator activity was significantly diminished. Remarkably, there seems to be a discrepancy between
the (low) tissue plasminogen activator activity and the (higher) plasminogen activator antigen concentration.
Alterations in the plasma concentrations of the investigated coagulation and fibrinolysis factors and in the
aggregability of the platelets are indicative of an involvement of coagulation, fibrinolysis and platelets in
hypertension, which can be considered äs partial risk factors for thrombophilia.
Introduction * - / i · \ ^ · ^ · t.hypertension (preeclampsia) than m those without
Hypertensive patients are at high risk for the devel- hypertension (8). In patients with borderline hyper-
opment of cardiovascular diseases (1), whereas several tension, even before the appearance of clinical man-
studies have shown that treatment of hypertension ifestations of vascular damages (9), coagulation acti-
diminishes the prevalence of cardiovascular diseases vation seems to be already present.
(2—5). The existence of hypertension, especially in ., , . , . .... , . .v , . . . , , . v /* - · Besides platelet aggregability and coagulation acti-combmation with other nsk factors, is disadvanta- .. * . . . , ,. . ,. _ ,. \ ,. ' „. vation, fibrinolysis, i.e. plasma tissue-type plasmino-geous for the prognosis of cardiovascular diseases (6). .. . *· ·* * u · r *.& F B . ^ v / gen activator activity, appears to be a major factor
The integrity of the blood vessels is essential, because related to the risk of cardiovascular disease (10 — 15).
damage of the intima (which may occur in hyperten- ^ ̂  study we .̂ ^ ^ coagulation/fibri.
•u«) can fmally cause atherosclerosis. Especial y thu no, ig ba,ance Jn jents wkh newl detected h
fand of patient is hkely to develop mcreasedl pfetelet ? usi relativd new sensitive methods for
aggregation with heart and blood vessel problems äs ^ measurement of coagulation activation (fibrin
possible sequelae (7). Moreover, blood vessel damage monomerS) thrombin-antithrombin III) and of the
activates the coagulation System, which may also stim- ^ of fibrino,ysis (D.diraerS) tissue piasminogen
ulate the progress of atherosclerosis. activator and plasminogen activator inhibitor). More-
Coagulation abnormalities in pregnant women have over, fibrinogen has been determined äs a known risk
been reported to be more serious in women with factor for cardiovascular disease (16, 17), äs well äs
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factor VIII , which, in increased plasma concentration,
is also suspected to be a factor involved in the devel-
opment of cardiovascular disease (18, 19).
Materials and Methods
Pat ien ts
As criteria of hypertension, we used the repeated raeasurement
of a diastolic pressure of ^ 130 mmHg both on the left and
righl hand side. Fifty-one patients meeting these criteria were
evaluated in this study. The group consisted of 29 males and
22 females, aged between 24 and 80 years (mean age 47 years).
The systolic pressure ranged from 130 — 200 mmHg (mean 164
mmHg), the diastolic pressure between 90 and 144 mmHg
(mean 104 mmHg). For the classification of the hypertension
we considered three subgroups: essential hypertension, renal
hypertension and hormonal hypertension. In this study, all
patients were classified äs belonging to the essential hyperten-
sion group. We excluded the presence of malignant hypertension
by fundoscopy, ECG and X-ray of the thorax. The reference
values were obtained from 50 subjectiveiy healthy individuals
aged 24—50 years (mean 40 years) and known to be without
hypenension.
Blood samples
Blood samples were drawn after fasting overnight, after a
resting period of 20 min. Except for tissue plasminogen acti-
vator activity, all coagulation and fibrinolysis parameters were
determined in citrated plasma. This was prepared by centrifu-
gation of a mixture of nine volumes freshly drawn blood with
one volume trisodium citrale (0.11 mol/1) for 30 min (1600g)
at 25 °C. The plasma was stored at —70 °C in plastic tubes and
thawed with tap water for 5 min before serial analysis. For the
measurement of tissue plasminogen activator activity a separate
tube was prepared with 0.5 ml acetate buffer (pH = 3.9) and
filled with l ml citrated blood. The tube was centrifuged im-
mediately (30 min, 1800#) and the plasma separated. The
collected plasma was acidified with 20% acetic acid (final pH
of the plasma sample 4.0-4.1), then stored at -70 °C in plastic
tubes; it was thawed with tap water for 5 min before analysis.
Methods
Fibrinogen was determined by the clotting assay of Clauss. The
von Willebrand factor was quantitated with an ELISA test kit
of Boehringer Mannheim Corp. (Mannheim, FRG).
For the factor VIII:c determination an activated partial throm-
bin time (aPTT) on stage clotting assay was performed, using
a deficient plasma from Behring (Marburg, FRG). Fibrin
monomer concentrations were assessed with the chromogenic
COA-Set FM-test of Kabi Vitrum Diagnostica. Thrombin-
antithrombin III was determined wilh an ELISA kit of the
Behring Corporation (Marburg, FRG). D-Dimer was assayed
in plasma with an ELISA method of Boehringer Mannheim
Corp. (Mannheim, FRG). For plasminogen activator inhibitor
the lest kit of Kabi Vitrum Diagnostiea COA-Set PAI was used.
The tissue-plasminogen activator activity test was also from
Kabi Vitrum Diagnostica äs well äs the antigenic tissue plas-
minogen activator test (Kabi Vitrum ttiagnostica, Coaliza t-
PA test). The piatelet aggregation tests were performed on
platelet-rich plasma which was prepared by immediate centrif-
ugation of citrated blood (prepared äs described above) at 200 g
for 10 minutes at room temperature. After gentle aspiration of
the platelet-rich-plasma, using a plastic pipette, the feriiaining
blood was centrifuged at 2000 £ for 10 min at room tempera-
ture, the resulting platelet-poor plasma was aspirated and sub-
sequently centrifuged at 10000g at 4°C for 10 min to obtain
platelet-free plasma. Platelet-rich plasma and platelet-free
plasma were used for standardization of the end concentration
of the piatelet count in the test. The ADP aggregation was
performed at a thrornbocyte concentration of 200 109/1·
Results
The summary statistics of the parameters are given in
table l. Small differences for mean and medium values
were found for fibrinogen, factor Vlllrc, von Wille-
brand factor, fibrin monomers and thrombiii-anti-
thrombin III complexes. From table 2 we can see that
only moderate percentages of the values are above
the upper reference limit for fibrinogen, factor VIII:c,
von Willebrand factor and thrombin-antithrombin III
(l5.7%, 9.8%, 11.8%, 11.8%), whereas for P-dimers,
tissue plasminogen activator antigen and plasminogen
activator inhibitor, intermediate percentages were ob-
tained (29.4%, 24.3% and 21.6%). Most remarkable
are the high percentages of values above the upper
reference ränge limit for fitirin monomers, and thpse
beneath the lower reference ränge limit for tissue
plasminogen activator activity (62.8%). The values
showed significant differences between the patient and
the reference group for fibrinogen, fibrin monomers,
thrombin-antithrombin III, D-dimers, tissue plasmin-
ogen activator activity, tissue plasminogen activator
antigen and plasminogen activator inhibitor (tab. 3).
In table 4 the results of the ADP (2 mol/l)-induced
piatelet aggregations are given. As can be seen it was
demonstrated that 33/51 (64.7%) of the patients had
Tab. 1. Summary statistics data of the hypertensive group (n = 51)
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Mean SD Mean SD
* Mann-Whitney-Wilcoxon test
Tab. 4. The ADP (2 μmol/l)-induced platelet aggregation in the control and the hypertensive patient group.








Tissue plasminogen activator activity















































































') The difference between the A«« of the reversible and the non-reversible group within the hypertensives was highly significant
(p < 0.0001).
n. f. = not found.
Amax = maximal amplitude of the aggregation pattern.
a reversible (normal) aggregation pattern and aggre-
gation intensity, whereas 18/51 (35.3%) of the patients
demonstrated a strengenthed (non-reversible) aggre-
gation pattern and significantly enhanced aggregation
maximum-values.
Discussion
Recently Panza et al. (20) concluded in their study on
abnormal endothelium-dependent vascular relaxation
in patients with essential hypertension, that endothe-
lium mediated vasodilation is impaired in patients
with essential hypertension. This defect might play an
important role in the functional abnormality of ele-
vated vascular resistance, which is observed in hyper-
tensive patients. Under regul r circumstances the pat-
ency of the blood vessels and the fluidity of the blood
is maintained by the endothelial cells. For this purpose
the endothelial cells synthesize a number of active
substances like fibronectin, heparan sulphate, inter-
leukin-1, tissue plasminogen activator, plasminogen
activator inhibitor, prostacyclin, nitric oxide, platelet-
activating factor and endothelin-1 (21, 22).
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Moreover the von Wittebrand factor is known to be
synthesized by endothelial cells, which is important
for the platelet-vessel wall interaction (18). Recently
Struyker Boudier et aL (23) summarized the three
mechanisms thought to be responsible for the overall
vascular resistance increase in hypertension: the rare-
faction of arterioles and capillaries, the decreased
internal diameter of the arterioles and the increase of
the arterial and arteriolar wall mass. We were there-
fore interested in possible interactions between the
more resistant vessel wall and platelets and coagula-
tion/fibrinolysis factors circulating in the blood.
In a considerable number of the patients (35.7%) we
found an enhanced in vitro reactivity towards ADP
(2 μιηοΙ/Ο-ίικΚκκα aggregation, which is in agreement
with earlier fmdings of Yamanishi et al. (24) in patients
with different stages of essential hypertension. One
could speculate that this phenomenon is a sequal of
the diminished prostacyclin synthesis and/or release
by the endothelial cells. Isles et al. (25) and Gavras et
al. (26) showed that malignant hypertension was as-
sociated with increased mean levels of fibrinogen,
factor VIII:c, decreased urokinase, increased fi-
brin(ogen) degradation products and decreased plate-
let count. In our patients with relatively mild hyper-
tension we can confirm the significant elevation of
the fibrinogen level, but not that of factor VIILc. We
demonstrated a significant decrease of tissue plasmin-
ogen activator activity, but a significant increase of
tissue plasminogen activator antigen and the level of
plasminogen activator inhibitor level.
The seeming discrepancy between activity and anti-
genic concentration has been described earlier by Nils-
son et al. (27) in patients with venous thrombosis and
defective fibrinolysis. The explanation therefore might
be the complex formation between plasminogen ac-
tivator and plasminogen activator inhibitor, which
can only be detected in the antigenic determination.
With regard to the significant enhancement of the
mean plasminogen activator inhibitor concentrations,
it should be mentioned that it has recently been re-
ported that two pools of plasminogen activator in-
hibitor-1 exist in blood, which may originate from
different cell types. The first one is the free plasma
pool, which might be synthesized and secreted by
endothelial cells and/or hepatocytes s reported by
Loskutoff (28) and Sprengers (39), but this is not
unambiguously established. The second pool of plas-
minogen activator inhibitor has been detennined in
the α-granules of the platelets (30) and thus in me-
gakaryocytes. The last pool might be the origin of the
increased plasminogen activtor inhibitor concentra^
tions in this patient group. As we could demonstrate
elevated platelet reactivity, which is indicative for
platelet activation, one might conclude that there will
be some platelet plasminogen activator inhibitor re-
lease, especially in the presence of a specific Stimulus
like thrombin.
That thrombin is present can be concluded from the
significantly enhanced mean values for thr mbin^an-
tithrombin III and fibrin monomers, whereas the
mean D-dimer levels are significantly enhanced too,
the mean value, however, being still within the refer-
ence r nge. n the basis of the percentages of values
above the upper reference r nge limit (for fibrin
monomers 60.8%, for D-dimer 29.4%) there seems
to be a discrepancy between coagulation activation
and reactive fibrinolysis, which is concordant however
with the behavio r of tissue plasminogen activator
activity and plasminogen activator inhibitor.
Besides platelet aggregability, tissue plasminogen ac-
tivator and plasminogen activator inhibitor have been
reported to be major risk factors for the development
of cardiovascular disease (10 — 15), whereas enhanced
fibrinogen levels have been reported to be related to
the additional enhanced risk for c rdiovascular dis?
ease (16, 17). In summary we therefore conclude that
both coagulation and fibrinolysis s well s the plate-
lets are impaired in hypertension and that a number
of risk factors for thrombophilia is present in this
group of hypertensive patients.
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